Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.

Yang C, Huntoon K, Ksendzovsky A, Zhuang Z, Lonser RR.

Cell Rep. 2013 Jan 31;3(1):52-9. doi: 10.1016/j.celrep.2012.12.007. Epub 2013 Jan 10.


E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.

Park KS, Kim JH, Shin HW, Chung KS, Im DS, Lim JH, Jung CR.

BMC Cancer. 2015 Oct 26;15:800. doi: 10.1186/s12885-015-1786-8.


In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.

Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.

Cancer Res. 2004 Dec 1;64(23):8595-603.


Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.


USP9X destabilizes pVHL and promotes cell proliferation.

Zhang C, Peng Z, Zhu M, Wang P, Du X, Li X, Liu Y, Jin Y, McNutt MA, Yin Y.

Oncotarget. 2016 Sep 13;7(37):60519-60534. doi: 10.18632/oncotarget.11139.


von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.

Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD.

Oncogene. 2011 Jul 14;30(28):3127-38. doi: 10.1038/onc.2011.40. Epub 2011 Feb 28.


VHL gene mutations and their effects on hypoxia inducible factor HIF╬▒: identification of potential driver and passenger mutations.

Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H.

Cancer Res. 2011 Aug 15;71(16):5500-11. doi: 10.1158/0008-5472.CAN-11-0757. Epub 2011 Jun 29.


Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.

Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T.

Oncol Rep. 2005 Jun;13(6):1033-41.


The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.

Zhou L, Yang H.

PLoS One. 2011;6(9):e23936. doi: 10.1371/journal.pone.0023936. Epub 2011 Sep 16.


Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.

Ding Z, German P, Bai S, Reddy AS, Liu XD, Sun M, Zhou L, Chen X, Zhao X, Wu C, Zhang S, Mills GB, Jonasch E.

Cancer Res. 2014 Jun 1;74(11):3127-36. doi: 10.1158/0008-5472.CAN-13-3213. Epub 2014 Apr 22.


WSB1 promotes tumor metastasis by inducing pVHL degradation.

Kim JJ, Lee SB, Jang J, Yi SY, Kim SH, Han SA, Lee JM, Tong SY, Vincelette ND, Gao B, Yin P, Evans D, Choi DW, Qin B, Liu T, Zhang H, Deng M, Jen J, Zhang J, Wang L, Lou Z.

Genes Dev. 2015 Nov 1;29(21):2244-57. doi: 10.1101/gad.268128.115.


Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.

J Biol Chem. 2002 Feb 15;277(7):4656-62. Epub 2001 Dec 5.


A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.

Iida K, Okimura Y, Takahashi K, Inomata S, Iguchi G, Kaji H, Chihara K.

Int J Mol Med. 2004 Mar;13(3):401-4.


Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.


The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.

Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y.

Arch Biochem Biophys. 2012 Feb 15;518(2):103-10. doi: 10.1016/ Epub 2012 Jan 3.


The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.


The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Kapitsinou PP, Haase VH.

Cell Death Differ. 2008 Apr;15(4):650-9. doi: 10.1038/sj.cdd.4402313. Epub 2008 Jan 25. Review.

Supplemental Content

Support Center